Evidence map›Paper›PMID 3874019›Full record

ArticleClinical and experimental immunology1985

Relationship between intensity of infection and immunomodulation in human schistosomiasis. II. NK cell activity and in vitro lymphocyte proliferation.

H Feldmeier, G A Gastl, U Poggensee, C Kortmann, A A Daffalla, H H Peter

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 1985. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Drugs for treating Schistosoma mansoni infection.The Cochrane database of systematic reviews · 2013
    Pooled it
  2. Immune Mechanisms Involved inFrontiers in immunology · 2018
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

H Feldmeier
G A Gastl
U Poggensee
C Kortmann
A A Daffalla
H H Peter

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cell activity against K-562 targets and lymphoproliferative responses to Con A, interleukin-2 (IL-2) and Con A + IL-2 were examined in a group of 41 Sudanese children suffering from schistosomiasis mansoni and haematobium. The results were correlated to the intensity of infection as determined by enumeration of parasite ova in urine and stool. NK cell activity measured at three effector to target cell ratios was significantly depressed in the patient group as compared to a German control group. Impairment of NK cell activity showed a direct relationship with the patients' parasite load. Furthermore lymphoproliferation to Con A, IL-2 and Con A + IL-2 was depressed in the group of patients. Interestingly the costimulation effect of IL-2 expressed as coefficient of delta ct/min(Con A + IL-2)/delta ct/minCon A correlated significantly to the intensity of infection suggesting that lymphocytes from heavily infected patients were defective in producing appropriate amounts of IL-2 in response to Con A. Our findings support the concept that heavy infections with S. mansoni and/or S. haematobium induce a peculiar dichotomy of cellular and humoral immune parameters. Whereas T cell-dependent cellular immune responsiveness and NK cell function decrease with increasing worm burden specific IgE and IgG antibody responses increase.

Indexed as

Cells, CulturedChildConcanavalin AFecesHumansInterleukin-2Killer Cells, NaturalLymphocyte ActivationLymphocytesMitosisParasite Egg CountSchistosomiasisConcanavalin AInterleukin-2

Identifiers

PMID3874019
PMCPMC1577033
OpenAlexW143959045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.